sorafenib has been researched along with Carcinoma, Non-Small Cell Lung in 96 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (25.00) | 29.6817 |
| 2010's | 59 (61.46) | 24.3611 |
| 2020's | 13 (13.54) | 2.80 |
| Authors | Studies |
|---|---|
| Song, M | 1 |
| Arthur, P; Gebeyehu, A; Kalvala, AK; Mondal, A; Nottingham, E; Patel, N; Rishi, AK; Singh, M; Surapaneni, SK | 1 |
| Guan, XY; Li, GB; Ma, X; Song, C; Wang, HL; Yang, LL; Yu, YM | 1 |
| Chen, X; Ren, J; Shao, M; Yang, H; Yang, W; Zheng, J | 1 |
| Acheampong, F; Halaweish, F; Mahnashi, M; Ostlund, T | 1 |
| Amin, NH; El-Saadi, MT; Mohamed, NR; Sharkawi, MMZ | 1 |
| Nijhawan, HP; Raut, HC; Yadav, KS | 1 |
| Alahmad, W; Bellur Atici, E; Cetinkaya, A; Kaya, SI; Ozkan, SA | 1 |
| Farrales, P; Gupta, V; Kanabar, DD; Kulkarni, NS; Kunda, NK; Muth, A; Parvathaneni, V; Shukla, SK | 1 |
| Liu, J; Zhao, YX | 1 |
| Amos, C; Cheng, C; Schaafsma, E; Weng, YL; Zhao, Y | 1 |
| Abdulla, DSY; Backes, H; Behringer, D; Buettner, R; Eichstaedt, M; Fischer, RN; Franklin, J; Frechen, S; Fuhr, U; Gardizi, M; Junge, L; Kaminsky, B; Kinzig, M; Kobe, C; Limburg, M; Mattonet, C; Merkelbach-Bruse, S; Michels, S; Nogova, L; Ouyang, D; Persigehl, T; Rokitta, D; Scheffler, M; Schnell, R; Sörgel, F; Sos, ML; Stelzer, C; Suleiman, AA; Taubert, M; Tian, Y; Wolf, J | 1 |
| Fletcher, P; Kunene, V; Ma, YT; Razak, RA | 1 |
| Fu, J; Wang, X; Yue, Q | 1 |
| Chen, C; Chen, W; Guo, L; Ju, R; Li, J; Shi, J; Sun, F; Ye, C; Zhang, D; Zhu, L | 1 |
| Kutkowska, J; Rapak, A; Strzadala, L | 1 |
| Chen, H; Chen, J; Cui, L; Li, M; Liu, X; Ren, Y; Sun, Y; Wang, L; Wang, X; Wu, C; Yang, J; Zhang, J; Zhou, W | 1 |
| Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Burris, HA; Gian, VG; Greco, FA; Hainsworth, JD; Kosloff, RA; Quinn, R; Rubin, MS; Shih, KC; Shipley, DL; Spigel, DR | 1 |
| Broggini, M; Caiola, E; Frapolli, R; Garassino, MC; Iezzi, A; Marabese, M; Tomanelli, M; Valerio, R | 1 |
| Chen, X; Ma, S; Mei, Q; Wang, J; Wang, Z; Zhang, S | 1 |
| Dai, JG; Huang, HH; Liang, Y | 1 |
| Hino, H; Hiramoto, M; Kazama, H; Lorenzo, A; Miyazawa, K; Moriya, S; Okuma, T; Ota, K; Takano, N; Yokota, A | 1 |
| He, X; Zhang, T | 1 |
| Alden, C; Blumenschein, GR; Davis, SE; Diao, L; Erasmus, J; Fossella, FV; Girard, L; Gupta, S; Herbst, RS; Heymach, JV; Hicks, ME; Hong, WK; Kies, MS; Kim, ES; Lee, JJ; Lippman, SM; Liu, S; Mao, L; Minna, JD; Peyton, M; Saintigny, P; Stewart, DJ; Tang, X; Tran, HT; Tsao, AS; Wang, J; Wistuba, I | 1 |
| Chen, W; Deng, J; Li, X; Wu, XY; Zhang, L; Zhang, YN; Zhong, CJ; Zhong, N | 1 |
| Li, Z; Wang, K; Zhang, H | 1 |
| Chang, FY; Chao, TT; Chen, KF; Chen, PT; Chen, YL; Shiau, CW; Su, WP; Tai, WT; Wang, CY; Weng, CY; Yu, CJ; Yuan, A | 1 |
| Bernards, R; Groenendijk, FH; Hauptmann, M; Horlings, HM; Jonkers, J; Mellema, WW; Schut, E; Smit, EF; van den Heuvel, MM; van der Burg, E; Willems, SM | 1 |
| Guo, DH; Pei, F; Si, HY; Tang, ZH; Wang, DX; Wang, WL; Xiao, BK; Xie, TT; Zhang, XY; Zhu, M | 1 |
| Alexandre de Azevedo, R; Barbuto, JA; Bydlowski, SP; Ferreira, AK; Jorge, SD; Levy, D; Pizzo, CR; Rodrigues, CP; Salomon, MA; Teixeira, SF | 1 |
| Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L | 1 |
| Ang, MK; Chau, NM; Chowbay, B; Haaland, B; Hui, KM; Koh, TS; Li, WY; Lim, WT; Ng, QS; Tan, DS; Tan, EH; Tan, IB; Thng, CH; Toh, CK | 1 |
| Arén, O; de Marinis, F; Hirsh, V; Juhász, E; Mok, TS; Novello, S; Ong, TJ; Paz-Ares, L; Peña, C; Schmelter, T; Seto, T; Smit, EF; Sun, Y; Wakelee, HA; Wu, YL; Yang, JC; Zhang, L | 1 |
| Cho, BC; Choi, JH; Choi, JR; Heo, DS; Jung, M; Kang, SY; Kim, DW; Kim, HT; Kim, JH; Kim, SW; Lee, DH; Lim, SM; Shim, HS | 1 |
| Horai, T; Horiike, A; Ishikawa, Y; Kaburaki, K; Kawano, Y; Kudo, K; Motoi, N; Nishio, M; Ohyanagi, F; Takeuchi, K; Tambo, Y; Tanimoto, A; Uenami, T; Yanagitani, N | 1 |
| Jimenez, CR; Knol, JC; Lind, JS; Pham, TV; Rovithi, M; Smit, EF; Verheul, HM; Voortman, J | 1 |
| Hu, P; Tang, F; Wang, Z; Xie, C | 1 |
| Casadei Gardini, A; Chiadini, E; Delmonte, A; Dubini, A; Faloppi, L; Frassineti, GL; Loretelli, C; Lucchesi, A; Marisi, G; Oboldi, D; Scartozzi, M; Ulivi, P | 1 |
| Gettinger, S | 1 |
| Blumenschein, G | 1 |
| Adjei, AA | 1 |
| Döme, B; Magyar, M | 1 |
| Horn, L; Sandler, AB | 1 |
| Dziadziusko, R; Fennell, D; Gridelli, C; Lacombe, D; Pallis, AG; Serfass, L; van Meerbeeck, JP; Welch, J | 1 |
| Fukuoka, M; Hatashita, E; Nakagawa, K; Okamoto, I; Takezawa, K; Yamada, Y; Yonesaka, K | 1 |
| Blumenschein, GR; Cihon, F; Cupit, L; Fossella, F; Gatzemeier, U; O'Leary, J; Reck, M; Stewart, DJ | 1 |
| Fukino, K; Fukuoka, M; Hasegawa, Y; Kaneda, H; Kawada, A; Miyazaki, M; Morinaga, R; Nakagawa, K; Okamoto, I; Satoh, T; Tanigawa, T; Ueda, S | 1 |
| Broxterman, HJ; de Haas, RR; Lind, JS; Smit, EF; van Hinsbergh, VW; Verheul, HM; Vroling, L | 1 |
| Le Moulec, S; Loriot, Y; Soria, JC | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Klar, U; Merk, J; Rolff, J; Sommer, A | 1 |
| Abrão Miziara, JE; Albert, I; Arén, O; Balint, B; Barrios, CH; Cihon, F; Csollak, M; Cupit, L; De Marinis, F; Dimatteo, S; Grossi, F; Hanna, N; Keller, A; Krzakowski, M; Novello, S; Pereira, JR; Reck, M; Scagliotti, G; Thomas, M; von Pawel, J | 1 |
| Bekers, O; Dingemans, AM; Giovannetti, E; Groen, HJ; Heideman, DA; Honeywell, RJ; Lind, JS; Peters, GJ; Postmus, PE; Smit, EF; Thunnissen, FB; van Suylen, RJ | 1 |
| Dingemans, AM; Hochstenbach, MM; Postmus, PE; Smit, EF; Thunnissen, FB; van Suylen, RJ | 1 |
| Bernard, S; Chiu, M; Davies, JM; Dees, EC; Dhruva, NS; Hayes, DN; Hilbun, LR; Ivanova, A; Keller, K; Kim, WY; Socinski, MA; Stinchcombe, TE; Walko, CM | 1 |
| de Ruysscher, D; Dingemans, AM; Lind, JS; Meijerink, MR; Ollers, MC; Postmus, PE; Smit, EF; van Kuijk, C | 1 |
| Berrino, L; Capasso, A; Ciardiello, F; De Vita, F; Eckhardt, SG; Martinelli, E; Morelli, MP; Morgillo, F; Orditura, M; Rodolico, G; Santoro, M; Troiani, T; Tuccillo, C; Vecchione, L; Vitagliano, D | 1 |
| Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G | 1 |
| Adjei, AA; Dy, GK; Hillman, SL; Mandrekar, S; Molina, JR; Nair, S; Rowland, KM; Schild, SE; Steen, PD; Wender, DB | 1 |
| Cao, L; Choyke, P; Force, J; Giaccone, G; Gutierrez, M; Keen, C; Kelly, RJ; Kummar, S; Lopez-Chavez, A; Raffeld, M; Rajan, A; Steinberg, SM; Turkbey, B; Wright, JJ; Xi, L; Yu, Y | 1 |
| Friedrich, MJ | 1 |
| Liu, Y; Shi, Y; Sun, Y; Wang, L; Wang, Y; Yu, S; Zhang, X | 1 |
| Danesi, R; Del Tacca, M; Mey, V; Pasqualetti, G; Ricciardi, S | 1 |
| El-Deiry, WS; Ferrara, TA; Katz, SI; Mayes, PA; Smith, CD; Wang, W; Zhou, L | 1 |
| Bass, JD; Burris, HA; Daniel, DB; Friedman, EK; Greco, FA; Hainsworth, JD; Mitchell, RB; Shipley, DL; Spigel, DR; Waterhouse, DM; Whorf, RC; Zangmeister, J | 1 |
| An, S; Choe, TB; Hong, SI; Jin, HO; Kim, YS; Lee, KH; Lee, SJ; Park, IC; Seo, SK; Woo, SH | 1 |
| Dombi, E; Force, J; Giaccone, G; Rajan, A; Steinberg, SM | 1 |
| Adjei, AA; Blumenschein, GR; Gatzemeier, U; Heigener, D; Hillman, S; Mandrekar, S | 1 |
| Keresztes, RS; Wu, S | 1 |
| Camidge, DR; Dasari, A; Diab, S; Drabkin, HA; Flaig, TW; Gore, L; Jimeno, A; Lewis, KD; Messersmith, WA; Weekes, CD | 1 |
| Jung, CK; Kang, JH; Kim, JO; Oh, JE; Shin, JY; Yoon, SA; Zhang, XH | 1 |
| Gold, KA; Kim, E; Zhang, J | 1 |
| Chen, J; Chen, L; Jiang, Y; Li, C; Li, Y; Ma, Y | 1 |
| Bria, E; Pilotto, S; Tortora, G | 1 |
| Alberola, V; Bennouna, J; Biesma, B; Eisen, T; Gans, S; Gottfried, M; Heigener, D; Le Marie, E; Liao, M; Montegriffo, E; Ong, TJ; Paz-Ares, LG; Santoro, A; Strauss, UP; Sun, Y; Syrigos, K; Vansteenkiste, J; von Pawel, J; Zhang, L | 1 |
| Dekker, H; Galvani, E; Giovannetti, E; Honeywell, R; Labots, M; Lind, JS; Peters, GJ; Sciarrillo, R; Smit, EF; Verheul, HM | 1 |
| Carbone, DP; Hanna, NH; Lee, JW; Schiller, JH; Traynor, AM; Wakelee, HA | 1 |
| Alden, C; Blumenschein, G; Davis, SE; Herbst, R; Hong, WK; Kim, E; Lee, JJ; Lippman, S; Liu, S; Stewart, D; Tang, XM; Tsao, AS; Wistuba, I | 1 |
| Dingemans, AM; Grigorieva, J; Groen, HJ; Kuiper, JL; Lind, JS; Roder, H; Roder, J; Smit, EF | 1 |
| Burgers, SA; Dingemans, AM; Groen, HJ; Heideman, DA; Kunst, PW; Mellema, WW; Smit, EF; Thunnissen, E; van Wijk, A | 1 |
| Levra, MG; Novello, S; Pelosi, E; Scagliotti, GV; Solitro, F; Vavalà, T; Veltri, A | 1 |
| Herbst, RS; Onn, A; Sandler, A | 1 |
| Ardizzoni, A; Franciosi, V; Tiseo, M | 1 |
| Brink, C; Carter, CA; Chen, C; Gilbert, KS; Maxuitenko, YY; Vincent, P; Waud, WR; Zhang, X | 1 |
| Chung, NM; Gutierrez, M; Turner, ML | 1 |
| Herbst, RS | 1 |
| Colantuoni, G; Comunale, D; De Vita, A; Del Gaizo, F; Ferrara, C; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A | 1 |
| Hanna, N | 1 |
| Adjei, AA; Croghan, G; Hanson, LJ; Jett, JR; Lathia, C; Mandrekar, SJ; Marks, R; Molina, JR; Reid, JR; Simantov, R; Xia, C | 1 |
| Bareschino, M; Ciardiello, F; Gridelli, C; Maione, P; Mongillo, F; Rossi, A | 1 |
| Cabebe, E; Wakelee, H | 1 |
| Karrison, TG; Maitland, ML; Ratain, MJ; Stadler, WM | 1 |
| Alba, E; Medina, MA; Quesada, AR | 1 |
| Stewart, DJ | 1 |
| Lee, CB; Socinski, MA | 1 |
| Buhl, R; Fischer, B | 1 |
18 review(s) available for sorafenib and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Topics: Antineoplastic Agents, Immunological; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Lung Neoplasms; Mutation; Prospective Studies; Sorafenib | 2022 |
Angiogenesis Inhibitors in NSCLC.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids | 2017 |
Efficacy and safety of sorafenib for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2014 |
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Targeted therapy in advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Sorafenib in lung cancer: clinical developments and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Forecasting; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factors | 2008 |
K-ras as a target for lung cancer therapy.
Topics: Benzamides; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Delivery Systems; Drugs, Investigational; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Risk Factors; Sensitivity and Specificity; Sorafenib; Survival Analysis; Treatment Outcome | 2008 |
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Xanthones | 2008 |
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2009 |
Targeted therapies in the treatment of advanced/metastatic NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Sorafenib in non-small cell lung cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Precision Medicine; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2012 |
Angiogenesis and lung cancer: prognostic and therapeutic implications.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib | 2005 |
Multi-target inhibitors in non-small cell lung cancer (NSCLC).
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Medical Oncology; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2006 |
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors | 2006 |
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2007 |
Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Models, Biological; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
[Lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drugs, Investigational; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Pneumonectomy; Pyridines; Pyrroles; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib | 2008 |
30 trial(s) available for sorafenib and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Proto-Oncogene Proteins p21(ras); Sorafenib | 2020 |
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Fatigue; Female; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinase Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Female; Humans; Lung Neoplasms; Metformin; Mice; Mice, Inbred BALB C; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Reactive Oxygen Species; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2015 |
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Canc
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Sorafenib; Treatment Outcome | 2015 |
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Risk Factors; Sorafenib; Treatment Outcome | 2016 |
Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Niacinamide; Peptides; Phenylurea Compounds; Proteomics; Proto-Oncogene Proteins p21(ras); Sorafenib; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome | 2016 |
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2009 |
Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Non-Small-Cell Lung; Demography; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Radiography; Sorafenib; Treatment Outcome | 2010 |
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Placebos; Pyridines; Sorafenib; Survival Rate; Treatment Outcome | 2010 |
A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Quinazolines; ras Proteins; Sorafenib; Vascular Endothelial Growth Factors | 2010 |
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Pemetrexed; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Contrast Media; Erlotinib Hydrochloride; Female; Humans; Iohexol; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Radiographic Image Enhancement; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib | 2010 |
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cytokines; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Genes, ras; Humans; Lung Neoplasms; Magnetic Resonance Angiography; Male; Middle Aged; Mutation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Sorafenib | 2011 |
[Randomize trial of cisplatin plus gemcitabine with either sorafenib or placebo as first-line therapy for non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Sorafenib | 2011 |
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Erlotinib Hydrochloride; Female; Gastrointestinal Diseases; Genes, erbB-1; Genes, ras; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Quinazolines; Salvage Therapy; Sorafenib; Treatment Outcome | 2011 |
Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Retrospective Studies; Sorafenib; Sulfonamides; Survival Rate; Thymoma; Thymus Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2011 |
Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2011 |
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kidney Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vorinostat | 2013 |
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Treatment Outcome | 2012 |
A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Salvage Therapy; Sorafenib; Survival Rate | 2012 |
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate; Tetrahydronaphthalenes | 2012 |
VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2012 |
A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Platinum; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib; Treatment Outcome | 2013 |
Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Niacinamide; Paclitaxel; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Sorafenib; Tomography, X-Ray Computed | 2013 |
Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Niacinamide; Pemetrexed; Phenylurea Compounds; Piperidines; Probability; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib | 2007 |
A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate | 2007 |
48 other study(ies) available for sorafenib and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Kinesins; Lung Neoplasms; Models, Molecular; Protein Conformation | 2015 |
Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer.
Topics: Acrylamides; Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Pyrimidines; Sorafenib; Spheroids, Cellular; Spiro Compounds; Telmisartan; Thiadiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Female; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sirtuin 2; Sorafenib; Synthetic Lethal Mutations; Xenograft Model Antitumor Assays | 2022 |
Estrone analogs as potential inhibitors targeting EGFR-MAPK pathway in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclin D; ErbB Receptors; Estrone; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Sorafenib | 2023 |
Determination of Gemcitabine and Sorafenib in Spiked Human Plasma Using Multivariate Model Update Chemometric Methods.
Topics: Carcinoma, Non-Small-Cell Lung; Chemometrics; Gemcitabine; Humans; Lung Neoplasms; Pharmaceutical Preparations; Sorafenib; United States | 2023 |
Inhalable spray-dried polycaprolactone-based microparticles of Sorafenib Tosylate with promising efficacy on A549 cells.
Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Polyesters; Polymers; Sorafenib | 2023 |
Designing an electrochemical sensor based on ZnO nanoparticle-supported molecularly imprinted polymer for ultra-sensitive and selective detection of sorafenib.
Topics: Carcinoma, Non-Small-Cell Lung; Electrochemical Techniques; Electrodes; Humans; Limit of Detection; Lung Neoplasms; Molecular Imprinting; Molecularly Imprinted Polymers; Polymers; Sorafenib; Zinc Oxide | 2023 |
Sorafenib Loaded Inhalable Polymeric Nanocarriers against Non-Small Cell Lung Cancer.
Topics: Administration, Inhalation; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cations; Cell Line, Tumor; Drug Carriers; Humans; Lung Neoplasms; Nanoparticles; Particle Size; Polymers; Sorafenib | 2020 |
Inhibitor of Differentiation 1 (ID1) Facilitates the Efficacy of Sorafenib in Non-Small Cell Lung Cancer Cells through Suppressing Epithelial to Mesenchymal Transition.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Differentiation Protein 1; Protein Kinase Inhibitors; RNA Interference; RNA, Small Interfering; Sorafenib | 2020 |
An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemotherapy, Adjuvant; Datasets as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Inhibitory Concentration 50; Liver Neoplasms; Logistic Models; Lung Neoplasms; Models, Genetic; Molecular Targeted Therapy; Mutation; Predictive Value of Tests; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; RNA-Seq; Signal Transduction; Sorafenib; Transcriptome | 2020 |
Association of Gastric Acid Suppression and Sorafenib Efficacy in Advanced Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Gastric Acid; Humans; Liver Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome; United Kingdom | 2021 |
Functional loss of TAGLN inhibits tumor growth and increases chemosensitivity of non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Male; Mice, Inbred BALB C; Microfilament Proteins; Muscle Proteins; Neoplasm Invasiveness; Neoplasm Metastasis; Sorafenib; Up-Regulation | 2020 |
Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Synergism; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Nanog Homeobox Protein; Niacinamide; Phenylurea Compounds; Sorafenib; Triazoles; Xenograft Model Antitumor Assays | 2017 |
Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells.
Topics: A549 Cells; Apoptosis; Betulinic Acid; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Combined Modality Therapy; Drug Synergism; Flow Cytometry; Humans; Mutation; Niacinamide; Pentacyclic Triterpenes; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Sorafenib; Triterpenes | 2017 |
Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Box Protein M1; Gefitinib; Gene Silencing; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; RNA, Neoplasm; Signal Transduction; Sorafenib; Stathmin; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Humans; Lung Neoplasms; Mutation; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyrimidines; Pyrimidinones; Sorafenib | 2018 |
The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.
Topics: Animals; Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Drug Therapy, Combination; Humans; Lung Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Clinical Drug Response Prediction by Using a Lq Penalized Network-Constrained Logistic Regression Method.
Topics: Algorithms; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Discovery; Erlotinib Hydrochloride; Female; Gene Expression Regulation; Gene Regulatory Networks; Genome, Human; Humans; Logistic Models; Lung Neoplasms; Male; Models, Biological; Precision Medicine; Sorafenib; Transcriptome | 2018 |
Fingolimod sensitizes EGFR wild‑type non‑small cell lung cancer cells to lapatinib or sorafenib and induces cell cycle arrest.
Topics: A549 Cells; Autophagy-Related Proteins; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Repositioning; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Fingolimod Hydrochloride; Humans; Lapatinib; Lung Neoplasms; Protein Kinase Inhibitors; Sorafenib | 2019 |
Alteration in the balance of prosurvival and proapoptotic signalling pathways leads to sequence-dependent synergism between docetaxel and sorafenib in human non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Interphase; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Taxoids | 2014 |
Stimulatory effects of sorafenib on human non‑small cell lung cancer cells in vitro by regulating MAPK/ERK activation.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin D1; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; MAP Kinase Kinase Kinases; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylation; Signal Transduction; Sorafenib | 2014 |
Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Pyrazoles; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cell Survival; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-raf; RNA, Small Interfering; Sorafenib; STAT3 Transcription Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Synergistic anti-tumor effects of the combination of a benzofuroxan derivate and sorafenib on NCI-H460 human large cell lung carcinoma cells.
Topics: Antineoplastic Agents; Benzoxazoles; Carcinoma, Non-Small-Cell Lung; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Stability; Signal Transduction; Sorafenib | 2016 |
Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.
Topics: Aged; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mutation; Neoplasms, Multiple Primary; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Sorafenib; Treatment Outcome | 2016 |
Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cyclin E; Drug Delivery Systems; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Genes, ras; Genotype; Humans; Lung Neoplasms; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2009 |
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glycoproteins; Hematopoietic Stem Cells; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Peptides; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib | 2010 |
[Targeting KRAS pathway in NSCLC therapy].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Farnesyltranstransferase; Genes, ras; Humans; Lung Neoplasms; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Quinolones; raf Kinases; ras Proteins; Sorafenib | 2009 |
Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epothilones; Gene Expression Profiling; Humans; Lung Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Xenograft Model Antitumor Assays | 2010 |
Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Sorafenib; Survival Rate; Treatment Outcome | 2010 |
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Cetuximab; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2010 |
NSCLC drug targets acquire new visibility.
Topics: Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Tetrahydronaphthalenes; Treatment Outcome | 2011 |
Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Signaling System; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Proto-Oncogene Proteins c-kit; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2011 |
FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease Models, Animal; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Recombinant Proteins; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2011 |
Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survivin; TOR Serine-Threonine Kinases | 2011 |
Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Blood Coagulation Disorders; Carcinoma, Non-Small-Cell Lung; Humans; Hypertension; Indoles; Intestinal Perforation; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Vascular Endothelial Growth Factor A; Wound Healing | 2011 |
Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Paclitaxel; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Pyridines; ras Proteins; Retinoblastoma Protein; Signal Transduction; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2012 |
The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; MAP Kinase Signaling System; Niacinamide; Pemetrexed; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib | 2012 |
Sorafenib for lung cancer: is the "Battle" still open?
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2012 |
Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Chromatography, Liquid; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Tandem Mass Spectrometry | 2013 |
Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytotoxins; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Vinblastine; Vinorelbine; Weight Loss; Xenograft Model Antitumor Assays | 2007 |
Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Foot; Hand; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Syndrome; Vasculitis, Leukocytoclastic, Cutaneous | 2006 |
Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Endpoint Determination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Sample Size; Sorafenib; Treatment Outcome | 2007 |
Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Endpoint Determination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Research Design; Sorafenib; Treatment Outcome | 2008 |